Rothenberger, Aribert

[["dc.bibliographiccitation.artnumber","3"],["dc.bibliographiccitation.journal","Child and Adolescent Psychiatry and Mental Health"],["dc.bibliographiccitation.volume","3"],["dc.contributor.author","Wehmeier, Peter M."],["dc.contributor.author","Schacht, Alexander"],["dc.contributor.author","Rothenberger, Aribert"],["dc.date.accessioned","2019-07-09T11:52:38Z"],["dc.date.available","2019-07-09T11:52:38Z"],["dc.date.issued","2009"],["dc.description.abstract","Background In many developed countries, the treatment of hyperkinetic disorder (or ADHD) consumes a considerable amount of resources. The primary aim of this study was to determine change in the direct cost of treatment for children and adolescents with hyperkinetic disorder in Germany over time, and compare the cost with the cost of treatment for two physical disorders: epilepsy and asthma. Methods The German Federal Statistical Office provided data on the direct cost of treating hyperkinetic disorder, epilepsy and asthma in Germany for 2002, 2004, and 2006. The direct costs of treatment incurred by hyperkinetic disorder in these years were compared with those incurred by epilepsy and asthma. Results The total direct cost of treatment for the hyperkinetic disorder was € 177 million in 2002, € 234 million in 2004, and € 341 million in 2006. The largest proportion of the cost was incurred by the age group < 15 years: € 158 million in 2002, € 205 million in 2004, and € 287 million in 2006. The direct cost of treatment for epilepsy in this age group was a total of € 157 million in 2002, € 155 million in 2004, and € 155 million in 2006. For asthma, the total direct cost of treatment in this age group was € 266 million in 2002, € 257 million in 2004, and € 272 million in 2006. Conclusion The direct cost of treatment for hyperkinetic disorder in the age group < 15 years increased considerably between 2002 and 2006. Over the same period of time and for the same age group, expenditure for epilepsy and asthma was more or less constant. The increase in expenditure for the treatment of hyperkinetic disorder may be due to increasing demand for diagnostic and therapeutic services and improved availability of such services. The study is limited by the difficulty of obtaining consistent data on the direct cost of treatment for both physical and psychiatric disorders in Germany."],["dc.identifier.doi","10.1186/1753-2000-3-3"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5770"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60243"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.subject.ddc","610"],["dc.title","Change in the direct cost of treatment for children and adolescents with hyperkinetic disorder in Germany over a period of four years"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","289"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","European Child & Adolescent Psychiatry"],["dc.bibliographiccitation.lastpage","296"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Breuer, Dieter"],["dc.contributor.author","Görtz-Dorten, Anja"],["dc.contributor.author","Rothenberger, Aribert"],["dc.contributor.author","Döpfner, Manfred"],["dc.date.accessioned","2019-07-09T11:53:20Z"],["dc.date.available","2019-07-09T11:53:20Z"],["dc.date.issued","2011"],["dc.description.abstract","DAYAS is a new two-part rating scale that assesses: (1) ADHD and ODD symptoms (externalising symptom ratings) and (2) symptomatology potentially related to ADHD medication (potentially medication-related symptoms) in real-world settings at different time periods throughout a normal school day. Data from a proof-of-concept study and two observational trials (Medikinet® retard [methylphenidate] and the Equasym XL® [methylphenidate] OBSEER study) evaluated: (1) validity of weekly externalising symptom ratings using DAYAS, in place of daily ratings; (2) reliability and internal consistency of DAYAS ratings for externalising symptoms and potentially medication-related symptoms; and (3) convergent and divergent validity of the externalising symptom ratings with existing validated scales. From the proof-of-concept study, daily scores by period of day and during the whole day correlated strongly with equivalent weekly scores (r = 0.83–0.92). Internal consistency of externalising symptom rating scales calculated from pooled data were acceptable or good by period of day (Cronbach’s alpha = 0.68–0.90) and very high for whole day scores (Cronbach’s alpha = 0.88–0.95). Internal consistency of the rating scale for potentially medication-related symptoms was also good for both teacher and parent ratings. From OBSEER data, correlations between FBB-ADHD total symptom scores and ratings on both parent and teacher versions of DAYAS were high (r = 0.73 and r = 0.84, respectively). Correlations between DAYAS and SDQ were highest for the SDQ subscales hyperactivity and conduct problems and substantially lower for pro-social behaviour, peers and emotional problems. The DAYAS rating scale had good internal consistency, and DAYAS scores correlated well with existing validated scales and the SDQ subscales hyperactivity and conduct problems. Weekly DAYAS scores (whole day and by period of day) could be considered a suitable replacement for daily assessment scores."],["dc.identifier.doi","10.1007/s00787-011-0206-0"],["dc.identifier.fs","583735"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7341"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60403"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","Springer"],["dc.publisher.place","Berlin/Heidelberg"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Assessment of daily profiles of ADHD and ODD symptoms, and symptomatology related to ADHD medication, by parent and teacher ratings"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","257"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","European Child & Adolescent Psychiatry"],["dc.bibliographiccitation.lastpage","265"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Rothenberger, Aribert"],["dc.contributor.author","Becker, Andreas"],["dc.contributor.author","Breuer, Dieter"],["dc.contributor.author","Döpfner, Manfred"],["dc.date.accessioned","2019-07-09T11:53:13Z"],["dc.date.available","2019-07-09T11:53:13Z"],["dc.date.issued","2011"],["dc.description.abstract","Attention deficit hyperactivity disorder (ADHD) impacts significantly on the quality of life (QoL) of patients and their families. Choice of therapy is increasingly influenced by treatment satisfaction and patient preference, with once-daily modified-release methylphenidate (MPH-MR) formulations offering clear benefits compared with immediate-release (IR) dosage forms. The effects of MPH-MR on QoL in ADHD have not been widely investigated and need more clarity in practice. The open-label OBSEER study evaluated the effectiveness and tolerability of Equasym XL®, a MPH-MR formulation, in routine practice. Children and adolescents (aged 6–17 years) with ADHD and attending school were included if Equasym XL® treatment was planned by the treating physician. Physicians, parents and patients completed questionnaires assessing QoL (KINDL; parent, child or adolescent versions), satisfaction with medication, adherence and treatment tolerability at baseline (Visit 1), 1–3 weeks (Visit 2) and 6–12 weeks (Visit 3) over a maximum 3-month observation period. Data from 822 consecutively referred patients were analysed. QoL and medication satisfaction increased from Visit 1 to Visit 3, with both patients and parents rating therapy with Equasym XL® as better than previous drug therapy. KINDL total score effect sizes were 0.67 (parents’ ratings), 0.52 (children’s ratings) and 0.51 (adolescents’ ratings; all p < 0.001). All KINDL subscores also increased: both parents and patients had the greatest improvement for school. Adherence to Equasym XL® was frequently rated as superior to prior treatment, particularly compared with MPH-IR repeated dosing. Treatment was generally well tolerated; approximately 3% of the patients discontinued treatment due to adverse events. Equasym XL® improved QoL compared with prior therapy, and resulted in good medication satisfaction and adherence in drug-naïve and previously treated patients."],["dc.identifier.doi","10.1007/s00787-011-0203-3"],["dc.identifier.fs","583733"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7140"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60371"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","Springer"],["dc.publisher.place","Berlin/Heidelberg"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","277"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","European Child & Adolescent Psychiatry"],["dc.bibliographiccitation.lastpage","288"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Döpfner, Manfred"],["dc.contributor.author","Breuer, Dieter"],["dc.contributor.author","Walter, Daniel"],["dc.contributor.author","Rothenberger, Aribert"],["dc.date.accessioned","2019-07-09T11:53:20Z"],["dc.date.available","2019-07-09T11:53:20Z"],["dc.date.issued","2011"],["dc.description.abstract","Methylphenidate (MPH) is the most commonly prescribed stimulant for children with ADHD. Data on the effects of different MPH formulations in real-life settings are scarce, and the role of previous therapy on treatment outcome when switching medications has not been well studied. OBSEER was an observational study designed to evaluate the effectiveness and safety of Equasym XL® in routine care. This study assessed whether the improvements reported with Equasym XL® are influenced by the degree of symptom control achieved with the previous medication. Patients enrolled in OBSEER were stratified by prior treatment (none, MPH-immediate release [IR] once daily [o.d.] [MPH-IR o.d.], MPH-IR repeated [MPH-IR >o.d.] and MPH-MR [modified release] excluding Equasym XL®), and changes in ADHD and other externalising symptoms (CGI-S, FBB-ADHD and DAYAS) and quality of life (QoL, KINDL) were evaluated during treatment with Equasym XL®. A total of 782 patients were analysed. Significant group-by-time interactions were found for all symptom variables analysed, indicating that effects varied by previous medication. For CGI-S and FBB-ADHD total scores, the greatest reductions in ADHD symptoms were observed in the treatment-naïve subgroup, followed (in order) by MPH-IR o.d., MPH-IR >o.d. and MPH-MR. A similar profile was seen for DAYAS ratings for all periods of the day except the evening, when there were no significant differences between subgroups. Similarly, the treatment-naïve and MPH-IR o.d. subgroups showed the greatest improvements in KINDL ratings. Although effects were greatest for treatment-naïve patients, improvements were also observed in the prior treatment subgroups for symptoms and QoL. This suggests that a change to Equasym XL® may be beneficial in patients with suboptimal effects on prior medication."],["dc.identifier.doi","10.1007/s00787-011-0205-1"],["dc.identifier.fs","583734"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7340"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60402"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","Springer"],["dc.publisher.place","Berlin/Heidelberg"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","An observational study of once-daily modified-release methylphenidate in ADHD: the effect of previous treatment on ADHD symptoms, other externalising symptoms and quality-of-life outcomes"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","743"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","European Child & Adolescent Psychiatry"],["dc.bibliographiccitation.lastpage","743"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Sergeant, Joseph A."],["dc.contributor.author","Banaschewski, Tobias"],["dc.contributor.author","Buitelaar, Jan"],["dc.contributor.author","Coghill, David"],["dc.contributor.author","Danckaerts, Marina"],["dc.contributor.author","Döpfner, Manfred"],["dc.contributor.author","Rothenberger, A."],["dc.contributor.author","Santosh, Paramala"],["dc.contributor.author","Sonuga-Barke, E. J. S."],["dc.contributor.author","Steinhausen, Hans-Christoph"],["dc.contributor.author","Taylor, Eric"],["dc.contributor.author","Zuddas, A."],["dc.date.accessioned","2011-07-21T15:09:55Z"],["dc.date.accessioned","2021-10-27T13:10:54Z"],["dc.date.available","2011-07-21T15:09:55Z"],["dc.date.available","2021-10-27T13:10:54Z"],["dc.date.issued","2010"],["dc.format.mimetype","application/pdf"],["dc.identifier.doi","10.1007/s00787-010-0125-5"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6777"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/91541"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.eissn","1435-165X"],["dc.relation.iserratumof","/handle/2/19048"],["dc.relation.issn","1018-8827"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Erratum to: Eunethydis: a statement of the ethical principles governing the relationship between the European group for ADHD guidelines, and its members, with commercial for-profit organisations"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","erratum_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","243"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","European Child & Adolescent Psychiatry"],["dc.bibliographiccitation.lastpage","255"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Döpfner, Manfred"],["dc.contributor.author","Görtz-Dorten, Anja"],["dc.contributor.author","Breuer, Dieter"],["dc.contributor.author","Rothenberger, Aribert"],["dc.date.accessioned","2019-07-09T11:53:20Z"],["dc.date.available","2019-07-09T11:53:20Z"],["dc.date.issued","2011"],["dc.description.abstract","ADHD affects over 5% of children worldwide. It is typically treated with stimulant medications, and methylphenidate (MPH) is the most commonly prescribed. This study investigated the effectiveness, on symptoms and impairment, and safety of Equasym XL®, a combination of 30% immediate-release and 70% modified-release MPH, in the treatment of ADHD in daily clinical practice. This open-label, observational, post-marketing surveillance study was conducted in 169 centres in Germany. Eligible patients, aged 6–17 years, were diagnosed with ADHD and about to begin treatment with Equasym XL®. Effectiveness was assessed by physicians using the clinical global impression (CGI) severity and improvement scales; teachers and parents completed questionnaires evaluating ADHD symptoms and behavioural problems (DAYAS, FBB-ADHD and SDQ-P). Assessments were carried out at baseline, after 1–3 and 6–12 weeks of treatment. Of 852 enrolled patients, 822 were evaluable; 25.30% were treatment naïve, 69.84% had previously received different MPH formulations, and 4.87% had received other medications. ADHD symptoms improved from baseline to last visit for the majority of patients for all outcome measures. According to physician ratings of core ADHD symptoms, 75.73% of patients showed improvements on the CGI-Improvement scale, 17.77% had no change, and 6.50% worsened. In teacher and parent ratings, the effectiveness of Equasym XL® was rated better than prior therapy at all measured time points across the day, particularly late morning (teachers) and early afternoon (parents). Equasym XL® was generally well tolerated; only 3.16% of patients permanently discontinued treatment due to adverse events. Equasym XL® is effective and well tolerated in daily clinical practice."],["dc.identifier.doi","10.1007/s00787-011-0202-4"],["dc.identifier.fs","583732"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7339"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60401"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","Springer"],["dc.publisher.place","Berlin/Heidelberg"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","267"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","European Child & Adolescent Psychiatry"],["dc.bibliographiccitation.lastpage","275"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Becker, Andreas"],["dc.contributor.author","Roessner, Veit"],["dc.contributor.author","Breuer, Dieter"],["dc.contributor.author","Döpfner, Manfred"],["dc.contributor.author","Rothenberger, Aribert"],["dc.date.accessioned","2019-07-09T11:53:14Z"],["dc.date.available","2019-07-09T11:53:14Z"],["dc.date.issued","2011"],["dc.description.abstract","Although ADHD significantly affects the quality of life (QoL) of patients and their families, QoL in children with ADHD has rarely been investigated in association with psychopathological profile, and the relationship remains unclear. The open-label OBSEER study evaluated the effectiveness and tolerability of Equasym XL®, a modified-release methylphenidate, in routine care of children and adolescents (aged 6–17 years) with ADHD. At baseline, questionnaires assessing psychopathological profile (Strengths and Difficulties Questionnaire, SDQ; parental ratings) and QoL (KINDL; parent, child or adolescent versions) were completed; QoL was reassessed at final visit. We analysed the relationship between psychopathology and parent/patient-rated QoL in ADHD at baseline. Data from 721 consecutively referred children and adolescents were analysed. QoL was similarly low from parent and self-ratings and independent of severity on the SDQ subscale hyperactivity/inattention. Self-ratings indicated that additional conduct disorder was associated with further reduction in QoL. Similarly, children with high scores from parent and adolescent ratings on the SDQ subscale conduct problems had reduced QoL on some KINDL subscales. Adolescents with ADHD not receiving medication at baseline reported lower QoL than those already on medication. Results show that children and adolescents with ADHD have low QoL, independent of core symptom severity. Additional conduct problems may further impact QoL negatively, while ADHD medication use may show a trend towards improved QoL. Not all psychopathological problems associated with ADHD affect QoL similarly. As parents appear to have a less critical view of QoL compared with children’s self-ratings, both parent and child ratings should be included in clinical assessments."],["dc.identifier.doi","10.1007/s00787-011-0204-2"],["dc.identifier.fs","579466"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7141"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60372"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","Springer"],["dc.publisher.place","Berlin/Heidelberg"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Relationship between quality of life and psychopathological profile: data from an observational study in children with ADHD"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","449"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Deutsches Ärzteblatt"],["dc.bibliographiccitation.volume","107"],["dc.contributor.author","Rothenberger, Aribert"],["dc.date.accessioned","2019-07-10T08:13:36Z"],["dc.date.available","2019-07-10T08:13:36Z"],["dc.date.issued","2010"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6863"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/61284"],["dc.language.iso","de"],["dc.notes.intern","Migrated from goescholar"],["dc.rights","Goescholar"],["dc.rights.access","openAccess"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject","Kinder- und Jugendpsychiatrie"],["dc.subject.ddc","610"],["dc.title","FRIEDRICH SPECHT - Streiter für die Kinder- und Jugendpsychiatrie"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","491"],["dc.bibliographiccitation.journal","Frontiers in Human Neuroscience"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Lange-Malecki, Bettina"],["dc.contributor.author","Treue, Stefan"],["dc.contributor.author","Rothenberger, Aribert"],["dc.contributor.author","Albrecht, Björn"],["dc.date.accessioned","2019-07-09T11:49:37Z"],["dc.date.available","2019-07-09T11:49:37Z"],["dc.date.issued","2018"],["dc.description.abstract","Performance deficits and diminished brain activity during cognitive control and error processing are frequently reported in attention deficit/hyperactivity disorder (ADHD), indicating a “top-down” deficit in executive attention. So far, these findings are almost exclusively based on the processing of static visual forms, neglecting the importance of visual motion processing in everyday life as well as important attentional and neuroanatomical differences between processing static forms and visual motion. For the current study, we contrasted performance and electrophysiological parameters associated with cognitive control from two Flanker-Tasks using static stimuli and moving random dot patterns. Behavioral data and event-related potentials were recorded from 16 boys with ADHD (combined type) and 26 controls (aged 8–15 years). The ADHD group showed less accuracy especially for moving stimuli, and prolonged response times for both stimulus types. Analyses of electrophysiological parameters of cognitive control revealed trends for diminished N2-enhancements and smaller error-negativities (indicating medium effect sizes), and we detected significantly lower error positivities (large effect sizes) compared to controls, similarly for both static and moving stimuli. Taken together, the study supports evidence that motion processing is not fully developed in childhood and that the cognitive control deficit in ADHD is of higher order and independent of stimulus type."],["dc.identifier.doi","10.3389/fnhum.2018.00491"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15729"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59595"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","Frontiers Media S.A."],["dc.relation.eissn","1662-5161"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Cognitive Control Over Visual Motion Processing – Are Children With ADHD Especially Compromised? A Pilot Study of Flanker Task Event-Related Potentials"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0207522"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","PLOS ONE"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Müller, Olga"],["dc.contributor.author","Rothenberger, Aribert"],["dc.contributor.author","Brüni, Geza L."],["dc.contributor.author","Wang, Biyao"],["dc.contributor.author","Becker, Andreas"],["dc.date.accessioned","2019-07-09T11:49:59Z"],["dc.date.available","2019-07-09T11:49:59Z"],["dc.date.issued","2018"],["dc.description.abstract","BACKGROUND: A previous study (Roessner et al. 2007) found psychopathological evidence of an additive model of the comorbid group with Chronic Tic Disorders and Attention Deficit Hyperactivity Disorder (CTD+ADHD), which demanded clinical interventions aimed primarily at the factor ADHD. This 14-year follow-up study tested whether this childhood additive model can also be found in young adulthood and whether ADHD remains the most impairing factor. METHODS: 92 patients (22.8% girls) from Roessner et al. (2007) were re-investigated as young adults at the age of 24 years, broken down into four groups: CTD-only (n = 22), CTD+ADHD (n = 23), ADHD-only (n = 24), and controls (n = 23). The Adult Behavior Checklist (ABCL) was used as an equivalent parent-report instrument to the Child Behavior Checklist (CBCL) applied 14 years ago. Statistically, 2x2 factorial design was completed. RESULTS: From the point of view of parents, the factors CTD and ADHD in young adults contributed almost equally to psychopathological problems and showed many interactions, i.e. an interactive model was supported. In addition, the ADHD factor was no longer the leading problem for psychosocial impairment in the adult CTD+ADHD group. CONCLUSION: The additive model of CTD+ADHD seems to exist no longer in young adults, nor may the childhood predominance of the factor ADHD in comorbid CTD+ADHD. Thus, treatment priority should be decided by clinicians on a case-by-case basis depending on the most impairing disorder of each patient."],["dc.description.sponsorship","Open-Access-Publiaktionsfons 2018"],["dc.identifier.doi","10.1371/journal.pone.0207522"],["dc.identifier.pmid","30458012"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15903"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15825"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59670"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Questioning the long-term stability of the additive model in comorbid CTD+ADHD - The transition from childhood to adulthood"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]